Boyang Wang, Immortal Dragons, explains how FDA’s Expedited IND Pilot and research partners could speed serial steps to first-in-human trials compared to China’s 818 Decree.
News|Articles|September 8, 2016
Microbial Contamination Leads to Recall of Eye-Wash Solutions
Author(s)Pharmaceutical Technology Editors
A customer complaint revealed microbial contamination issues affecting lots with expiration dates in late 2018 and early 2019.
Advertisement
FDA has posted news that Rugby Laboratories and Major Pharmaceuticals, through efforts with their distributor, United Exchange Corp. (Cerritos, Calif), are recalling lots of purified water-based products: Rugby eye irrigating solution and Major eye wash, due to microbial contamination issues.
These problems, which could result in potentially sight-threatening eye infections for anyone using affected product, were brought to the attention of the manufacturers by a customer complaint. Both products were distributed throughout the US to wholesale and retail facilities, including hospitals and pharmacies. The companies are notifying distributors and customers of the recall by letter, and arranging for return of all recalled products.
The recall affects Major EyeWash lot numbers G15905-G15912 and G16901-G16907, as well as G16910 and G16911, with expiration dates in October and November 2018, and January through March 2019. Also affected are Rugby EyeWash lots G15908, 15909, 16904, 16908, 16912 and 16913, with expiration dates in October and November 2018 and January through March 2019.
Source:
Advertisement
Related to this article
This article examines how modern automation platforms create the digital foundation required for Pharma 4.0 by integrating manufacturing systems, centralized data management, Industrial Internet of Things connectivity, electronic batch production records, and AI-driven analytics.
The FDA approves oral pritelivir for drug-resistant herpes sores in immunocompromised patients; what it means for antiviral development and manufacturing.
This week, drug formulation and manufacturing experts showcased their knowledge, and companies exhibited their products, at CPHI Milan.
FDA approves Teva’s Weltruza, a once-monthly subcutaneous olanzapine for schizophrenia whose copolymer depot eliminates post-injection monitoring.
Equivalence test using two one-sided tests are widely used for demonstrating the comparability of treatment effects in different research fields. The method described in the manuscript aims to use simulations in Microsoft Excel to compute power for 2 one-sided tests for two groups with unequal variances.
Susan J. Schniepp, distinguished fellow with Nelson Labs, and Siegfried Schmitt, PhD, vice president, Technical, with Parexel, clear up some of the confusion about what does and does not need to be complied with regarding standards set by international pharmacopoeias.
Mitigating nitrosamine risk requires assessing each product individually, says Bram Baert, Global Head of Regulatory Affairs at Capsugel, and Sandrine Picco, Senior Analytical Specialist on Capsugel's Innovaform Accelerator Team, in this interview with PharmTech.
Advertisement
Advertisement
Trending on Pharmaceutical Technology
1
What the Olanzapine Depot Approval Means for CMC Teams
2
Q&A: Patient-Centric Drug Development Should Start at Product Definition
3
Pritelivir Shifts Resistant Herpes Care from Intravenous to Oral
4
Clinical Trial Delays: FDA’s Expedited IND Pilot vs China’s 818 Decree
5